165 related articles for article (PubMed ID: 19102671)
1. GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability.
Costa E; Chen Y; Dong E; Grayson DR; Kundakovic M; Maloku E; Ruzicka W; Satta R; Veldic M; Zhubi A; Guidotti A
Expert Rev Neurother; 2009 Jan; 9(1):87-98. PubMed ID: 19102671
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling.
Guidotti A; Dong E; Kundakovic M; Satta R; Grayson DR; Costa E
Trends Pharmacol Sci; 2009 Feb; 30(2):55-60. PubMed ID: 19110320
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation.
Dong E; Grayson DR; Guidotti A; Costa E
Epigenomics; 2009 Oct; 1(1):201-11. PubMed ID: 22122643
[TBL] [Abstract][Full Text] [Related]
4. Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia.
Dong E; Agis-Balboa RC; Simonini MV; Grayson DR; Costa E; Guidotti A
Proc Natl Acad Sci U S A; 2005 Aug; 102(35):12578-83. PubMed ID: 16113080
[TBL] [Abstract][Full Text] [Related]
5. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation.
Dong E; Nelson M; Grayson DR; Costa E; Guidotti A
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13614-9. PubMed ID: 18757738
[TBL] [Abstract][Full Text] [Related]
6. DNA-methyltransferase1 (DNMT1) binding to CpG rich GABAergic and BDNF promoters is increased in the brain of schizophrenia and bipolar disorder patients.
Dong E; Ruzicka WB; Grayson DR; Guidotti A
Schizophr Res; 2015 Sep; 167(1-3):35-41. PubMed ID: 25476119
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic downregulation of GABAergic function in schizophrenia: potential for pharmacological intervention?
Costa E; Grayson DR; Guidotti A
Mol Interv; 2003 Jun; 3(4):220-9. PubMed ID: 14993449
[No Abstract] [Full Text] [Related]
8.
Dong E; Locci V; Gatta E; Grayson DR; Guidotti A
Mol Pharmacol; 2019 Jan; 95(1):62-69. PubMed ID: 30397000
[TBL] [Abstract][Full Text] [Related]
9. The human reelin gene: transcription factors (+), repressors (-) and the methylation switch (+/-) in schizophrenia.
Grayson DR; Chen Y; Costa E; Dong E; Guidotti A; Kundakovic M; Sharma RP
Pharmacol Ther; 2006 Jul; 111(1):272-86. PubMed ID: 16574235
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder.
Veldic M; Kadriu B; Maloku E; Agis-Balboa RC; Guidotti A; Davis JM; Costa E
Schizophr Res; 2007 Mar; 91(1-3):51-61. PubMed ID: 17270400
[TBL] [Abstract][Full Text] [Related]
11. DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains.
Veldic M; Caruncho HJ; Liu WS; Davis J; Satta R; Grayson DR; Guidotti A; Costa E
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):348-53. PubMed ID: 14684836
[TBL] [Abstract][Full Text] [Related]
12. Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters.
Dong E; Guidotti A; Grayson DR; Costa E
Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4676-81. PubMed ID: 17360583
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic GABAergic targets in schizophrenia and bipolar disorder.
Guidotti A; Auta J; Chen Y; Davis JM; Dong E; Gavin DP; Grayson DR; Matrisciano F; Pinna G; Satta R; Sharma RP; Tremolizzo L; Tueting P
Neuropharmacology; 2011 Jun; 60(7-8):1007-16. PubMed ID: 21074545
[TBL] [Abstract][Full Text] [Related]
14. [Epigenetic model in the pharmacologic modulation of vulnerability to schizophrenia].
Tremolizzo L
Encephale; 2007 Nov; 33(Pt 3):867-9. PubMed ID: 18402359
[No Abstract] [Full Text] [Related]
15. GABAergic cortical neuron chromatin as a putative target to treat schizophrenia vulnerability.
Costa E; Grayson DR; Mitchell CP; Tremolizzo L; Veldic M; Guidotti A
Crit Rev Neurobiol; 2003; 15(2):121-42. PubMed ID: 14977367
[TBL] [Abstract][Full Text] [Related]
16. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon.
Guidotti A; Auta J; Davis JM; Dong E; Grayson DR; Veldic M; Zhang X; Costa E
Psychopharmacology (Berl); 2005 Jul; 180(2):191-205. PubMed ID: 15864560
[TBL] [Abstract][Full Text] [Related]
17. Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability.
Costa E; Davis J; Grayson DR; Guidotti A; Pappas GD; Pesold C
Neurobiol Dis; 2001 Oct; 8(5):723-42. PubMed ID: 11592844
[TBL] [Abstract][Full Text] [Related]
18. Methylation status of the reelin promoter region in the brain of schizophrenic patients.
Tochigi M; Iwamoto K; Bundo M; Komori A; Sasaki T; Kato N; Kato T
Biol Psychiatry; 2008 Mar; 63(5):530-3. PubMed ID: 17870056
[TBL] [Abstract][Full Text] [Related]
19. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability.
Tremolizzo L; Carboni G; Ruzicka WB; Mitchell CP; Sugaya I; Tueting P; Sharma R; Grayson DR; Costa E; Guidotti A
Proc Natl Acad Sci U S A; 2002 Dec; 99(26):17095-100. PubMed ID: 12481028
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report.
Abdolmaleky HM; Cheng KH; Russo A; Smith CL; Faraone SV; Wilcox M; Shafa R; Glatt SJ; Nguyen G; Ponte JF; Thiagalingam S; Tsuang MT
Am J Med Genet B Neuropsychiatr Genet; 2005 Apr; 134B(1):60-6. PubMed ID: 15717292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
